1. Home
  2. AMTB vs VOR Comparison

AMTB vs VOR Comparison

Compare AMTB & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amerant Bancorp Inc.

AMTB

Amerant Bancorp Inc.

N/A

Current Price

$28.58

Market Cap

1.2B

Sector

Finance

ML Signal

N/A

Logo Vor Biopharma Inc.

VOR

Vor Biopharma Inc.

N/A

Current Price

$23.82

Market Cap

1.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AMTB
VOR
Founded
1979
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.4B
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
AMTB
VOR
Price
$28.58
$23.82
Analyst Decision
Buy
Buy
Analyst Count
3
10
Target Price
$23.67
$45.33
AVG Volume (30 Days)
395.7K
773.6K
Earning Date
04-23-2026
05-11-2026
Dividend Yield
1.57%
N/A
EPS Growth
386.36
N/A
EPS
0.97
N/A
Revenue
N/A
N/A
Revenue This Year
$8.29
N/A
Revenue Next Year
$7.67
N/A
P/E Ratio
$29.66
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.62
$1.90
52 Week High
$30.60
$49.95

Technical Indicators

Market Signals
Indicator
AMTB
VOR
Relative Strength Index (RSI) 54.09 60.10
Support Level $21.68 $21.75
Resistance Level $30.60 $24.34
Average True Range (ATR) 0.64 1.13
MACD -0.23 -0.18
Stochastic Oscillator 29.74 54.84

Price Performance

Historical Comparison
AMTB
VOR

About AMTB Amerant Bancorp Inc.

Amerant Bancorp Inc is a bank holding company. Through its bank, it provides individuals and businesses deposit, credit, investment, wealth management, and fiduciary services, both in the United States and to select international customers. The bank also provides banking services through traditional channels, such as banking centers and ATMs, as well as via secure websites, mobile devices and telephones.

About VOR Vor Biopharma Inc.

Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.

Share on Social Networks: